Compare SiTime Corporation (SITM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? SiTime Corporation trades at $609.78 (market cap $19.42B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: SiTime Corporation is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SiTime Corporation for 18 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SITM | XBI | |
|---|---|---|
Market Cap | $19.42B | $10.11B |
Volume | 360,307 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $901.60 | $169.55 |
52-Week Low | $252.76 | $104.99 |
Typical Hold Time | 18 Days | 38 Days |
Enterprise Value | $18.82B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SITM is trading at $665.16, down 6.46% over the past 24 hours, with a bullish technical signal supported by moving averages. The company shows strong revenue growth momentum with Q2 2026 revenue surging 126.5% year-over-year to $157.43 million, marking its first GAAP profit. Analyst consensus remains strongly positive with 9 buy ratings and a $751.43 price target representing 13% upside potential. Recent institutional activity includes California State Teachers Retirement System increasing its stake by 73,098.9% during the latest quarter.
The outlook remains positive driven by AI infrastructure demand and the Renesas acquisition, though valuation metrics appear elevated with P/E at 1,076 and P/S at 36.9. Key risks include execution challenges in scaling operations and potential market volatility. The stock's current position near recent highs suggests cautious optimism is warranted despite strong growth fundamentals.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
